Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal CancerAntonio Avallone, Alfredo Budillon, Vincenza Granata et al.|JAMA Network Open|2021Cited by 34
Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with <i>RAS</i> -mutated metastatic colorectal cancer: the REVOLUTION study protocolAntonio Avallone, Alfredo Budillon, Maria Carmela Piccirillo et al.|Therapeutic Advances in Medical Oncology|2020Cited by 17
Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer: The IMPROVE TrialAntonio Avallone, Alfredo Budillon, Francesco Giuliani et al.|Journal of Clinical Oncology|2024Cited by 14
Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II studyClaudia Cardone, Antonio Avallone, Alfonso De Stefano et al.|ESMO Open|2023Cited by 6
Is whole body low dose CT still necessary in the era of <sup>18</sup>F-FDG PET/CT for the assessment of bone disease in multiple myeloma patients?Nicola Maggialetti, Giuseppe Rubini, Cristina Ferrari et al.|PubMed|0Cited by 4